CRISPR Therapeutics Advances Gene-Editing Treatments Towards Late-Stage Trials Amidst Growing CASGEVY Demand
CRISPR Therapeutics is preparing to move several experimental gene-editing treatments into late-stage trials, according to executives at a Jefferies fireside chat. The company's CTX310, zugo-cel, and CTX611 programs are anticipated to enter late-stage trials within approximately a year. Early results for CTX310, a one-time treatment targeting ANGPTL3 for lipid reduction, showed a 63% mean reduction in triglycerides at day 30 in a severe hypertriglyceridemia study. For zugo-cel, an investigational allogeneic CAR T therapy, six out of seven scleroderma patients in a cohort showed an early CRISS-25 response. The Phase II study for CTX611, which targets Factor XI to reduce venous thromboembolism events, has concluded enrollment, with top-line data expected by year-end. The company also reports growing demand for its commercial product, CASGEVY, which is nearing a $100 million revenue run rate in the prior quarter. CRISPR Therapeutics, headquartered in Zug, Switzerland, with U.S. operations in Cambridge, Massac...